Clinical trials: Ganglion
Parkinsons Disease
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on…
- Trial name
- PADOVA (NCT04777331)
- Testing
- Prasinezumab
- Where
- 110 sites in United States, Austria and 7 more
- Volunteers
- 586 people
- Sponsor
- Hoffmann-La Roche
Wilson's Disease
Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).
A randomised, open-label study evaluating the pharmacokinetics, safety, and tolerability of a new once daily dose of 900mg of TETA 4HCL by comparing it against the current marketed Cuprior® formulation (450mg trientine base…
- Trial name
- NCT06128954
- Testing
- 900mg TETA 4HCl Once Daily Formulation, 900mg TETA 4HCl Cuprior®
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Orphalan
Parkinson's Disease
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the…
- Trial name
- STRIDE-PD (NCT00099268)
- Testing
- Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
- Where
- 73 sites in United States, Austria and 12 more
- Volunteers
- 747 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson Disease
Deep Brain Stimulation (DBS) Frequency Effects on Gait in Parkinson's Disease(PD)
In this study the investigators will evaluate the effect of both low and high frequency Deep Brain stimulation of the subthalamic nucleus (STN) in Parkinson's patients who have noted a change in their walking.
- Trial name
- NCT00993291
- Testing
- Frequency change to 60 Hz, Frequency change to 130 Hz
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University
Parkinson's Disease
Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease
Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and uncontrolled movements called dyskinesias. A drug called amantadine can reduce these movements.
- Trial name
- NCT00794313
- Testing
- Amantadine 300 mg, Topiramate, Sugar Pill
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Oregon Health and Science University
Parkinson Disease
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
- Trial name
- NCT02687542
- Testing
- PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD), PF-06649751 middle dose 2 (7 mg QD)
- Where
- 57 sites in United States, Canada and 4 more
- Volunteers
- 108 people
- Sponsor
- Pfizer
Parkinson's Disease (PD)
Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067
The purpose of this study is to assess the tolerability of BIA 9-1067 after multiple rising dose regimens of BIA 9-1067.
- Trial name
- NCT02071810
- Testing
- BIA 9-1067
- Where
- France
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease, Cognitive Impairment
Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia
The purpose of this research is to evaluate the usefulness of memantine, compared to placebo (sugar pill), for the treatment of cognitive impairment in patients with idiopathic Parkinson's disease (PD) and dementia.
- Conditions
- Parkinson's Disease, Cognitive Impairment, Dementia
- Trial name
- NCT00294554
- Testing
- Memantine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Parkinson Disease
Study to Assess PDM608 in Healthy Adult Subjects
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of PDM608 in healthy adult subjects.
- Trial name
- NCT05950906
- Testing
- PDM608
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Calibr, a division of Scripps Research
Huntington's Disease
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
The study is designed as a multi-site, prospective, 15-month longitudinal, cohort study measuring CSF mHTT in participants with early manifest Stage I or Stage II Huntington's Disease (HD).
- Trial name
- NCT03664804
- Testing
- No Study Drug was Administered in this Study
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease
A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients
The primary objective of this trial is to establish the maximum maintenance dose of SPM 962 in patients with Parkinson's disease in a multi-center, uncontrolled, open-label study by conducting safety evaluation of each patient…
- Trial name
- NCT01634243
- Testing
- SPM 962
- Where
- 5 sites in Japan
- Volunteers
- 64 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Parkinson Disease, Amyotrophic Lateral Sclerosis
Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's…
- Trial name
- PROBE (NCT05542576)
- Testing
- AMDX2011P
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Amydis Inc.
Tourette Syndrome
Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
This is a study to evaluate the efficacy and safety of deutetrabenazine (TEV-50717) tablets for the reduction of motor and phonic tics associated with TS in children and adolescents 6 through 16 years of age.
- Trial name
- ARTISTS1 (NCT03452943)
- Testing
- TEV-50717
- Where
- 42 sites in United States, Canada and 4 more
- Volunteers
- 119 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Huntington Disease, Chorea
Atomoxetine and Huntington's Disease
The purpose of this research study is to evaluate the effect of atomoxetine (also known as Strattera) compared to placebo (inactive substance) on daily activities such as attention and focus, thinking ability and muscle movements…
- Trial name
- NCT00368849
- Testing
- atomoxetine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Iowa
Huntington Disease
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
- Trial name
- NCT05358821
- Testing
- SAGE-718
- Where
- 14 sites in United States, Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Huntington Disease
Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease
Cellavita HD is a stem-cell therapy for Huntington's Disease. This is a prospective, phase II, single-center, randomized (2:2:1), triple-blind, placebo controlled study, with two test doses of Cellavita HD product.
- Trial name
- ADORE-DH (NCT03252535)
- Testing
- Cellavita HD lower dose, Cellavita HD higher dose
- Where
- Brazil
- Volunteers
- 49 people
- Sponsor
- Azidus Brasil
Parkinson Disease
Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease
This study is a placebo-controlled, double-blind trial that will investigate the safety and tolerability of molecular hydrogen, a promising antioxidant agent, in patients with early-stage Parkinson's Disease.
- Trial name
- NCT03971617
- Testing
- Hydrogen
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stony Brook University
Parkinson Disease
Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528
This open label extension study allows assessment of the long term safety profile of REQUIP PR in subjects who have completed 24 weeks of randomised treatment in study ROP111528.
- Trial name
- NCT01536574
- Testing
- Requip PR
- Where
- 18 sites in China
- Volunteers
- 295 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease
Cognitive Training in Parkinson's Disease
The purpose of this research study is to determine whether cognitive training will improve cognitive and brain functions in people with Parkinson's Disease (PD) during activities of daily living using cognitive evaluations and…
- Trial name
- NCT05495997
- Testing
- Mental Imagery Training, Psychoeducation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Multiple System Atrophy
Exenatide Once-weekly as a Treatment for Multiple System Atrophy
Fifty patients with early stage Multiple System Atrophy (MSA) will be recruited and randomised to receive Exenatide injections, or to act as controls in this open label trial.
- Trial name
- MSA (NCT04431713)
- Testing
- Exenatide Pen Injector [Bydureon]
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London